0 (0%)		11-11 20:53
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	46.41	1-year :	54.21
Resists	First :	39.74	Second :	46.41
Pivot price	38.28
Supports	First :	36.75	Second :	34.9
MAs	MA(5) :	38.79	MA(20) :	37.88
	MA(100) :	33.43	MA(250) :	31.77
MACD	MACD :	0.8	Signal :	0.9
%K %D	K(14,3) :	71.5	D(3) :	74
RSI	RSI(14): 60.4
52-week	High :	39.74	Low :	23.04

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ STK ] has closed below upper band by 41.0%. Bollinger Bands are 64.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	39.18 - 39.37	39.37 - 39.56
Low:	37.95 - 38.19	38.19 - 38.43
Close:	38.17 - 38.55	38.55 - 38.92

Tue, 11 Nov 2025
General Member Offer: 15% Off Food & Non-Alcoholic Beverages at STK Steakhouse, Disney Springs - D23

Tue, 11 Nov 2025
STK-012 Plus Pembrolizumab, Chemo Demonstrate Safety and Efficacy in NSCLC - Targeted Oncology

Mon, 10 Nov 2025
Synthekine reports initial STK-012 data in lung cancer trial - Clinical Trials Arena

Mon, 10 Nov 2025
Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer - BioSpace

Sun, 09 Nov 2025
Frontline STK-012 Plus Pembrolizumab and Chemo Shows Early Promise in PD-L1–Negative NSCLC - OncLive

Sat, 08 Nov 2025
Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC - CancerNetwork

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	17 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	14.8 (%)
Shares Short	9 (K)
Shares Short P.Month	5 (K)

EPS	2.44
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	15.82
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0.46
Forward Dividend	0
Dividend Yield	1.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.